OmniLytics Announces USDA/FSIS Allowance of Bacteriophage Treatment of Salmonella on Poultry

Salt Lake City — (July 29, 2008) OmniLytics, Inc. today announced the issuance of a no objection letter from the USDA’s Food Safety and Inspection Service (FSIS) for use of Salmonella targeted bacteriophages from OmniLytics, Inc. applied to poultry. This poultry application will be jointly pursued in connection with OmniLytics collaboration with Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY).

The bacteriophage products will be used to reduce the level of Salmonella contamination on the feathers of live poultry before processing. Reducing the amount of Salmonella coming into the processing facility will not only help existing interventions to operate more effectively but also could help reduce the contamination that can find its way to the grocery store and ultimately to the consumer.

“Salmonella contamination in the processing of poultry products continues to raise grave concerns for industry, consumers and regulatory agencies alike,” said Justin Reber, president and CEO of OmniLytics. “The USDA’s allowance of our bacteriophage technology is a huge step toward the creation of a safe, natural product that’s specifically targeted to reduce Salmonella,”

The FSIS letter is an important milestone on the road toward development of a commercial product for poultry producers. A description of the letter can be found on the FSIS website at the following link: http://www.fsis.usda.gov/Regulations_&_Policies/New_Technology_Table_Feb_06/index.asp.

Bacteriophages, ubiquitous in nature, kill individual strains and species of bacteria. The specificity of bacteriophages allows targeting of harmful bacteria without compromising the viability of other beneficial microflora or fauna. Identified in 1917, bacteriophages or “bacteria eaters” are environmentally friendly, biodegradable, and have no effect on non-target organisms, plants, animals or humans.

About OmniLytics, Inc.

OmniLytics is a bacteriophage company focused on developing safe, natural solutions the first company to work with any United States regulatory agency on a submission claiming bacteriophage as the active ingredient, and with the approval of its AgriPhage product in 2005, it became the first company to receive a registered label. OmniLytics continues to expand its research and development of bacteriophage solutions for control of microorganisms in agricultural, food & water, industrial, pharmaceutical, and defense markets. OmniLytics’ proprietary formulas and processes optimize the use of natural bacteriophage for commercial applications.
For more information about OmniLytics, visit www.omnilytics.com.

Contacts:

Press or Product

Alan Walbeck
OmniLytics, Inc.
801.746.3600 x320
awalbeck@omnilytics.com

Contact the OmniLytics PR Department Here.